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SUMMARY
Cancer cells exhibit many abnormal phenotypes that induce apoptotic signaling via the intrinsic, or
mitochondrial, pathway. That cancer cells nonetheless survive implies that they select for blocks in
apoptosis. Identifying cancer-specific apoptotic blocks is necessary to rationally target them. Using
a panel of 18 lymphoma cell lines, we show that a strategy we have developed, BH3 profiling, can
identify apoptotic defects in cancer cells and separate them into three main classes based on
position in the apoptotic pathway. BH3 profiling identifies cells that require BCL-2 for survival and
predicts sensitivity to the BCL-2 antagonist ABT-737. BCL-2 dependence correlates with high levels
of proapoptotic BIM sequestered by BCL-2. Strikingly, BH3 profiling can also predict sensitivity to
conventional chemotherapeutic agents like etoposide, vincristine, and adriamycin.INTRODUCTION
Apoptosis, a form of programmed cell death (PCD), can be
triggered by numerous types of cellular damage and
derangement. Genomic instability, oncogene activation,
cell cycle checkpoint violation and loss of prosurvival
signaling all have been shown to induce apoptosis via
the intrinsic apoptotic pathway. Cancer cells often exhibit
some or all of these ‘‘deadly’’ phenotypes. To survive,
therefore, it is necessary that cancer cells select for a block
in apoptotic signaling at the mitochondrion. Such blocks
likely involve alterations in the function and control of the
BCL-2 family of proteins. Understanding these blocks is
essential for selective therapeutic targeting of apoptotic
pathways in cancer cells.
Proteins of the BCL-2 family are key mediators of
programmed cell death at the mitochondria (Figure 1A)
(Danial and Korsmeyer, 2004; Green and Kroemer, 2004;Wang, 2001). They may be conveniently broken into three
main groups based on sequence homology and function
(Cory and Adams, 2002; Gross et al., 1999). BAX and
BAK, also known as multidomain proapoptotic proteins
or ‘‘effectors,’’ share homology in the BCL-2 homology
(BH) 1, 2, and 3 regions. The antiapoptotic proteins, includ-
ing BCL-2, MCL-1, BCL-XL, BCL-w, and BFL-1/A1, share
homology in the BH1, BH2, BH3, and BH4 domains. The
proapoptotic BH3-only family members are so named
because they share homology only in the BH3 domain,
which is essential for prodeath function. In response to
damage and derangement signals, BH3-only proteins are
activated, either by stabilization of protein, increased tran-
scription, or posttranslational modification (Huang and
Strasser, 2000; Kelekar and Thompson, 1998; Wei et al.,
2000). Certain of the BH3-only proteins, including BID
and BIM, are called ‘‘activators,’’ and induce activation
by causing an allosteric change in BAX and BAK (CartronSIGNIFICANCE
The key to effective rational therapies is the identification of targets that are required for cancer cell survival but
dispensable for normal cell survival. Due to death signaling generated by their phenotypic aberrancies, cancer
cells require blocks in cell death pathways not required by normal cells. Here we present a method, BH3 profiling,
for identifying apoptotic blocks in cancer cells and separating them into three distinct classes. We identify cancer
cells that depend upon the block conferred by BCL-2 expression. These cells can be killed by a compound, ABT-
737, that antagonizes BCL-2 function. Furthermore, BH3 profiling can identify cancer cells already heavily primed
with death signals. Significantly, these cells are more sensitive to conventional agents like etoposide, vincristine,
and adriamycin.Cancer Cell 12, 171–185, August 2007 ª2007 Elsevier Inc. 171
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BH3 Profiling Sorts Apoptotic Blocks in CancerFigure 1. Three Distinct Classes of Apoptotic Blocks in
Diffuse Large B Cell Lymphoma Cells
(A) Model of BCL-2 family control over mitochondrial apoptosis. In
response to damage or derangement, activators activate effectors,
causing mitochondrial permeabilization and commitment to death.
Antiapoptotic proteins sequester activators to prevent their contacting
effectors, and sensitizers act as selective antagonists of antiapoptotic
proteins. Adapted from Certo et al. (2006).
(B) Three possible apoptotic blocks that cancer cells might select to
escape apoptosis.172 Cancer Cell 12, 171–185, August 2007 ª2007 Elsevier Inc.et al., 2004; Certo et al., 2006; Desagher et al., 1999;
Kuwana et al., 2002; Letai et al., 2002; Luo et al., 1998;
Marani et al., 2002; Wei et al., 2000). Recent evidence
has been presented that as an intact protein PUMA may
also function as an activator (Kim et al., 2006). BAX and
BAK oligomerization follows, with subsequent mitochon-
drial outer membrane permeabilization (MOMP). BAX
and BAK activation and MOMP may be considered the
critical steps at which point the cell is irretrievably com-
mitted to PCD. BAX and BAK are absolutely essential
for the proapoptotic function of BH3-only proteins, and
deficiency of BAX and BAK affords broad protection
from apoptosis against numerous insults (Wei et al.,
2001; Zong et al., 2001). Multiple proapoptotic factors
are released following MOMP, including cytochrome c,
AIF, and SMAC (Wang, 2001). Resulting widespread
proteolysis by the family of cysteine proteases, known
as caspases, induces cellular dysfunction and the tagging
of the cell with signals that trigger the engulfment of the
apoptotic cell by phagocytic cells.
Antiapoptotic proteins like BCL-2 oppose PCD primarily
by binding and sequestering activator BH3-only proteins,
preventing their activation of BAX and BAK (Certo et al.,
2006; Cheng et al., 1996, 2001; Kuwana et al., 2005; Letai
et al., 2002). The hydrophobic face of the BH3 domains’
amphipathic a helix binds into a hydrophobic groove
formed by the BH1, BH2, and BH3 domains of the antia-
poptotic proteins (Cheng et al., 1996; Kelekar et al.,
1997; Kelekar and Thompson, 1998; Muchmore et al.,
1996; Sattler et al., 1997). Antiapoptotic proteins also
bind BAX and BAK, particularly in their activated mono-
meric forms (Hsu et al., 1997; Hsu and Youle, 1997).
When a cell or mitochondrion contains antiapoptotic
proteins that are largely occupied by activator BH3-only
proteins due to ongoing death signaling, we describe
that cell type as ‘‘primed for death’’ (Certo et al., 2006).
Cells that are primed for death are uniquely dependent
on the function of antiapoptotic proteins of the BCL-2
family for survival. We have thus far found that being
‘‘primed for death’’ is more common among malignant
than among nonmalignant cells.
A second class of proapoptotic BH3-only proteins,
called ‘‘sensitizers,’’ are unable to induce activation of
BAX and BAK directly. Rather, they exert their proapop-
totic function by competing for the BH3 domain-binding
cleft in antiapoptotic proteins, displacing or preventing
the binding of activators (Certo et al., 2006; Kuwana
et al., 2005; Letai, 2003; Letai et al., 2002). Sensitizers
may thus be considered inhibitors of the inhibitors of
apoptosis. BH3 domains that behave as sensitizers
include BAD, BIK, NOXA, BMF, Harakiri (HRK), and
PUMA (Certo et al., 2006).
An important recent observation is that interactions
between members of the sensitizer BH3-only class and
the antiapoptotic class are selective (Certo et al., 2006;
Chen et al., 2005; Kim et al., 2006; Kuwana et al., 2005;
Opferman et al., 2003). For instance, while BCL-2 is bound
and antagonized by the BAD BH3 domain, NOXA BH3
binds BCL-2 very poorly. The exactly opposite pattern is
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domains of the sensitizers exhibit selective inhibitory inter-
actions with antiapoptotic proteins, we realized that they
could be exploited as probes of antiapoptotic protein func-
tion. Therefore, using a strategy we call ‘‘BH3 profiling,’’ we
can determine (1) if the cell is ‘‘primed for death’’ and (2) if
the cell is primed, which antiapoptotic protein(s) are
primarily responsible for maintaining survival (Certo et al.,
2006).
BH3 profiling is a potentially powerful tool in determining
how cancer cells evade apoptosis. To perform BH3 profil-
ing, mitochondria are isolated from the cell of interest and
then exposed to a series of peptides derived from the BH3
domains of BH3-only proteins. The ability of these
peptides to induce mitochondrial permeabilization is
measured by cytochrome c release. In model systems,
the ability of activator BH3 domains to induce cytochrome
c release indicates the presence of either BAX or BAK. The
ability of sensitizer BH3 domains to induce cytochrome c
release implies the presence of BAX and BAK, but also
the presence of antiapoptotic protein(s) primed with a pro-
tein capable of activating BAX or BAK, as sensitizer BH3
peptides lack this function. By examining the pattern of
sensitizer BH3 peptides that induce cytochrome c release,
the identity of the antiapoptotic protein necessary for
maintaining survival can be identified by comparison to
a table summarizing the interaction pattern between the
antiapoptotic proteins and the range of BH3 domains
(Certo et al., 2006).
We have previously used BH3 profiling for the interroga-
tion of the intrinsic, or mitochondrial, apoptotic pathway in
chronic lymphocytic leukemia (CLL) (Del Gaizo Moore
et al., 2007). We found that BH3 profiling was very effective
in demonstrating the uniform BCL-2 expression and
BCL-2 dependence of the many CLL samples tested.
This dependence was reflected in a uniform sensitivity of
CLL cells from chemotherapy-naive patients to the
BCL-2 antagonist ABT-737. While this study was instruc-
tive regarding CLL biology, the homogeneity of apoptotic
blocks represented in our CLL samples did not allow us
to investigate the wider range of apoptotic blocks
employed by cancer cells. In order to study cancers that
escape apoptosis by a wider variety of mechanisms we
turned to a more heterogeneous disease, diffuse large B
cell lymphoma (DLBCL). In DLBCL, roughly 15% of cases
express high levels of BCL-2 due to the t(14;18) transloca-
tion, which places the BCL-2 gene under the control of the
immunoglobulin heavy chain gene transcriptional ele-
ments. In another subset of DLBCL, BCL-2 is overex-
pressed as a result of gene amplification or gain of an extra
copy of chromosome 18, whereas others show high
BCL-2 expression without identifiable genetic abnormal-
ity. Remaining cases, which may represent at least half
of al DLBCL, show little expression of BCL-2 and thus
must rely on a different apoptotic block (Gascoyne et al.,
1997; Iqbal et al., 2006; Kramer et al., 1996). We turned
to a large panel of 18 DLBCL cell lines as a model system
to study classes of apoptotic escape exploited by cancer
cells.Many chemotherapeutic agents kill cancer cells via
apoptosis, and there is considerable interest and invest-
ment in the direct targeting of abnormal apoptotic path-
ways in cancer (Letai, 2005). It is therefore of crucial
importance to investigate methods that can rapidly and
convincingly decipher the abnormalities in the cell death
pathways in cancer cells to better understand the critical
phenomena of therapeutic resistance and sensitivity. In
order to address this question, we needed a range of
cancer cells that evaded apoptosis in heterogeneous
ways but that were otherwise biologically similar. For
this reason, we turned to the study of apoptotic abnormal-
ities in the most common lymphoid malignancy, diffuse
large B cell lymphoma.
In this study, we analyzed a panel of 18 diffuse large B
cell lymphoma cell lines with tools that included BH3
profiling. We found that we were able to assign cells to
one of three classes based on the type of apoptotic block
they possessed. Membership in these classes was pre-
dictive of response to a BCL-2 antagonist as well as to
conventional chemotherapy. These findings show that
identification of the class of apoptotic block in cancer cells
is potentially of great clinical importance and utility.
RESULTS
BH3 Profiling Detects Three Classes of Apoptotic
Blocks in Lymphoma Cells
A priori, one can consider three distinct ways that cancer
cells might select to block intrinsic apoptotic signaling
generated by their abnormal phenotypes (Figure 1B). First,
upstream activation of BH3-only proteins might be
inhibited (class A block). Second, the effector arm of the
apoptotic pathway might be blunted by loss of BAX and
BAK (class B block). Finally, activation of BAX and BAK
might be prevented via expression of antiapoptotic pro-
teins like BCL-2 and MCL-1 (class C block). Note that cells
with a class C block are those we describe as being
‘‘primed for death’’ and would be detectable by mitochon-
drial sensitivity to sensitizer BH3 domains in BH3 profiling.
It should also be noted that presence of any one block
does not rule out the presence of another, though one
might expect selection pressure for additional blocks to
be attenuated after selection for an effective initial block.
We initiated our studies of lymphoma in four lymphoma
cell lines: SU-DHL4, SU-DHL6, SU-DHL8, and SU-DHL10
cell lines. These were chosen because two contained the
t(14;18) (SU-DHL4, SU-DHL6), while the other two did not.
To perform BH3 profiling, we tested the ability of a panel of
sensitizer peptides to induce mitochondrial outer mem-
brane permeabilization (MOMP) in mitochondria isolated
from the lymphoma cells. For easy reference, Figure 2A
shows the interaction pattern between the BH3 peptides
and antiapoptotic proteins. MOMP was measured by
quantifying cytochrome c release by ELISA.
BH3 profiling proved able to distinguish these three
classes of blocks in our sample of four lymphoma lines
(Figure 2). SU-DHL4 and SU-DHL6 demonstrated class
C blocks. They showed a ‘‘primed’’ phenotype, basedCancer Cell 12, 171–185, August 2007 ª2007 Elsevier Inc. 173
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BH3 Profiling Sorts Apoptotic Blocks in CancerFigure 2. BH3 Profiling of SU-DHL4, -6, -8, and -10 Cells Discriminates Three Distinct Classes of Apoptotic Blocks
(A) Interaction pattern between BH3 peptides and antiapoptotic proteins (Certo et al., 2006). Red indicates high-affinity binding, orange indicates low-
affinity binding, and green indicates undetectable binding. Mitochondria were isolated from SU-DHL4 (B), SU-DHL6 (C), SU-DHL8 (D), and SU-DHL10
(E) cells, and incubated with a panel of BH3 peptides (100 mM). Release of cytochrome c was determined by a comparison of cytochrome c in the
pellet and supernatant quantitated by ELISA. Results were shown as percentage minus solvent control DMSO values, and mean of triplicates
with error bars for standard deviation. (F) Protein lysates were prepared and subjected to immunoprecipitation with an antibody specific for human
BCL-2 (6C8, Phamingen). Both lysates (left) and immunoprecipitates (right) were separated by denaturing electrophoresis. Membranes were blotted
with antibodies against BCL-2 family proteins as indicated. Actin was a loading control.on the sensitivity to sensitizer BH3 peptides. Note that
a strong response to the PUMA BH3 peptide, which inter-
acts with all of the antiapoptotic proteins, provides a useful
gauge of whether the mitochondria are primed. The pat-
tern of sensitivity (PUMA, BMF, BAD, ± BIK) indicated
a dependence on BCL-2 for SU-DHL4. SU-DHL6 also
was primed, as shown by a strong PUMA BH3 and BMF
BH3 signal. The weaker, but definite, response to both
of the more selective BH3 peptides BAD BH3 and NOXA
A BH3 implicate combined dependence on BCL-2 and
MCL-1. SU-DHL8 appeared to be poorly primed, given
the limited response to PUMA BH3 and other sensitizers,
but nonetheless demonstrated an intact effector arm by
responding strongly to activators BIM BH3 and BID174 Cancer Cell 12, 171–185, August 2007 ª2007 Elsevier IncBH3. This suggested a class A block for SU-DHL8. SU-
DHL10 responded poorly to both sensitizer and activator
peptides, indicating the loss of the effector arm, suggest-
ing a class B block.
BH3 profiling predicted that SU-DHL4 and SU-DHL6
would exhibit priming by an activator BH3-only protein,
that SU-DHL8 would be poorly primed, and that SU-
DHL10 would lack BAX and BAK. To test these predic-
tions, we examined the abundance of BCL-2 family pro-
teins and complexes of BCL-2 with other members of
the BCL-2 family (Figure 2F). BIM was present in high
levels in SU-DHL4 and SU-DHL6, and it was likewise
sequestered in a complex with BCL-2. Notably, SU-
DHL4, which showed singular dependence on BCL-2,.
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which showed dependence on both BCL-2 and MCL-1,
showed higher levels of MCL-1 than SU-DHL4. BIM
expression was nearly undetectable in SU-DHL8, consis-
tent with the class A block shown by BH3 profiling.
Whereas uncleaved BID was present in roughly equal
amounts in all four cell lines, the active cleaved form of
BID was not detected, and there was very little BID seen
in complex with BCL-2 in any of the cells. Strikingly, the
class B block shown by BH3 profiling had also predicted
the nearly undetectable levels of BAX and BAK in SU-
DHL10, in stark contrast to the expression levels in the
other three cell lines. Thus, BH3 profiling accurately
assessed the mechanisms of apoptotic block present in
all four cell lines. It furthermore accurately predicted the
abundance of key proteins and protein complexes.
BH3 Profiling Predicts Response to ABT-737
Next, we investigated whether this single test also
correctly predicted sensitivity to BCL-2 antagonism by
ABT-737. BAD BH3 response and a BCL-2-dependent
pattern from BH3 profiling have previously been strong
predictors of cellular response to ABT-737 in other models
(Certo et al., 2006; Del Gaizo Moore et al., 2007). There-
fore, BH3 profiling predicts in this case a response of
SU-DHL4 and SU-DHL6, but not SU-DHL8 or SU-
DHL10, to ABT-737. We tested this prediction by generat-
ing a dose-response curve to ABT-737 for each of the cell
lines (Figure 3A). Clearly, the cell lines demonstrate sensi-
tivity and resistance exactly as predicted by BH3 profiling
Figure 3. BH3 Profiling Predicts Sensitivity to BCL-2 Antago-
nism by ABT-737
SU-DHL4, -6, -8, and -10 cells were treated with increasing doses of
ABT-737 (A) or its negative control enantiomer (enant, B) for 48 hr
and stained with Annexin V-FITC for flow cytometry analysis. Viability
was shown as a percentage of control (DMSO-treated) cells with stan-
dard deviation of triplicates shown by error bars.(EC50 140 nM and 250 nM for SU-DHL4 and SU-DHL6,
respectively, >>10,000 nM for SU-DHL8 and SU-
DHL10). Supporting action by the intended mechanism
of BCL-2 antagonism, all four cell lines showed very
limited toxicity from treatment with an enantiomer of
similar physiochemical properties, but much lower affinity
to BCL-2 (Oltersdorf et al., 2005) (Figure 3B).
BCL-2 and BIM:BCL-2 Complex Levels
Quantitatively Predict Sensitivity to ABT-737
Above we showed that relatively high abundance of the
BCL-2:BIM complex predicted sensitivity to ABT-737.
To test how generalizable this predictor is, we examined
a larger panel of lymphoma cell lines. First, we prepared
dose-response curves for each of the 18 cell lines, which
demonstrated a wide range of EC50 (Figure 4A). To vali-
date the use of BH3 profiling in this additional cohort of
lymphoma cell lines, we tested the ability of BH3 profiling
to distinguish apoptotic blocks in two cell lines that both
bore the t(14;18), but which had very different responses
to ABT-737 (TOLEDO, EC50 = 74 nM; PFEIFFER, EC50 =
5619 nM) (Figures 4B and 4C). Both profiles demonstrate
a class C block. In the case of TOLEDO, the pattern of
response to BH3 peptides suggests that BCL-2 is primar-
ily responsible for the class C block, consistent with sen-
sitivity to ABT-737. For PFEIFFER, however, the pattern
suggests protection by a protein other than BCL-2, con-
sistent with relative resistance to ABT-737. The pattern,
in fact, is more suggestive of protection by the antiapop-
totic protein BFL-1, which is not antagonized by ABT-
737 (see Figure 2A) (Certo et al., 2006; Oltersdorf et al.,
2005). In support of the selective importance of BFL-1 in
the PFEIFFER cell line, we found that levels of BFL-1
mRNA expression are much higher in PFEIFFER than in
any of the other cell lines studied by BH3 profiling
(Figure 4D). Note that of these seven cell lines, only
PFEIFFER revealed a pattern suggestive of BFL-1 depen-
dence. Thus, results of BH3 profiling here again accurately
predict response to ABT-737 and expression of BCL-2
family proteins.
Next, we again examined the abundance of BCL-2
family proteins and complexes by immunoblots of cell
lysates (Figure 4E) and immunoprecipitates of BCL-2
(Figure 4F). We quantified the intensity of the bands by
gel densitometry, as presented in Table 1. Note that abso-
lute levels of other targets of ABT-737, BCL-w, and BCL-
XL were much lower than those of BCL-2 as established
by comparison to recombinant standards (Figure S2 in
the Supplemental Data available with this article online).
Thus, no further studies of BCL-w and BCL-XL were pur-
sued. Note also that BID was found to be uncleaved and
not in complex with BCL-2 throughout the cell lines, and
therefore unlikely to be playing a role in BCL-2 depen-
dence or sensitivity to ABT-737 (Figures 4E and 4F).
We examined the ability of the different protein and
complex levels to dictate response to ABT-737 by a linear
regression analysis of protein or complex abundance and
log EC50. We found that levels of BCL-2 (Figure 5A) and
BCL-2:BIM complex (Figure 5B) quantitatively predictedCancer Cell 12, 171–185, August 2007 ª2007 Elsevier Inc. 175
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BH3 Profiling Sorts Apoptotic Blocks in CancerFigure 4. Sensitivity to ABT-737 Falls across a Wide Range in a Panel of Lymphoma Cell Lines
(A) A panel of 14 DLBCL cell lines (not including the SU-DHL4, -6, -8, and -10 cells shown in Figure 3) was examined for their sensitivity to ABT-737.
Cells were treated with increasing doses of ABT-737 for 48 hr and stained with Annexin V-FITC for flow cytometry analysis as in Figure 3. Shown are
the means of experiments performed in triplicate. Dose-response curves indicating highest sensitivity are red, those indicating intermediate sensitivity
are yellow, and those indicating low sensitivity are blue.
(B and C) (B) and (C) were BH3 profiling results for DLBCL cell lines TOLEDO and PFEIFFER, respectively. The assays were performed with 100 mM
BH3-only peptides as in Figure 2. Shown is the mean of three experiments; error bars show standard deviation.
(D) Relative mRNA levels of BFL-1 found in seven lymphoma cell lines.
(E) Immunoblot analysis of BCL-2 family proteins in lysates prepared from the 14 DLBCL cell lines with indicated antibodies.
(F) Immunoblot analysis of immunoprecipitates prepared from the same lysates in (E) using an antibody against human BCL-2 (6C8) for immunopre-
cipitation. Sample numbers correspond to sample names as shown in Table 1.sensitivity to ABT-737 better than any of the other proteins
or complexes. Levels of BCL-2:BAX complex (Figure 5C)
and BAX (Figure 5D) also correlated with response to
ABT-737, though the correlation was weaker than for176 Cancer Cell 12, 171–185, August 2007 ª2007 Elsevier Inc.BCL-2 or BCL-2:BIM. Correlation of MCL-1 and log EC50
did not reach statistical significance (p = 0.081, r2 =
0.18), but there is a weak trend for higher MCL-1 levels
to reduce sensitivity to ABT-737. Notably, BIM and BAK
Cancer Cell
BH3 Profiling Sorts Apoptotic Blocks in CancerTable 1. SummaryofDensitometric Analysis of Immunoblots, EC50 of ABT-737, and t(14: 18) Status in 18DLBCLCells
Sample Name Sample No. BCL-2 MCL-1 BIM BAX BAK BIM (IP) BAX (IP) EC50 (nM) t(14:18)
SU-DHL5 1 2 196 8 32 122 0 0 20,000 negative
SU-DHL7 2 177 29 11 70 138 22 129 807 negative
OCI-Ly1 3 228 127 51 97 97 139 273 21 positive
OCI-Ly4 4 26 128 3 60 120 10 8 20,000 negative
OCI-Ly7 5 0 101 5 32 99 6 4 20,000 negative
OCI-Ly8 6 140 8 7 13 52 36 30 1216 positive
OCI-Ly18 7 224 28 39 57 86 100 274 159 positive
DB 8 185 46 35 131 108 60 264 279 positive
FARAGE 9 15 70 2 55 66 7 10 2769 negative
HT 10 2 74 0 58 103 9 5 20,000 negative
KARPAS 422 11 220 105 53 129 87 11 2 350.6 positive
PFEIFFER 12 69 312 275 57 219 45 7 5619 positive
WSU-NHL 13 127 43 28 0 59 62 4 2405 positive
TOLEDO 14 158 99 183 93 172 108 52 74 positive
SU-DHL6 15 124 128 16 92 109 38 349 250 positive
SU-DHL4 16 97 116 37 76 100 28 0 140 positive
SU-DHL8 17 36 256 12 51 145 5 13 20,000 negative
SU-DHL10 18 32 268 41 17 8 8 30 20,000 negative
Immunoblots, shown in Figure 4D (lysates), Figure 4E (immunoprecipitates [IP]), and Figure S1 (where SU-DHL4, -6, -8, and -10
samples were normalized to cell lines OCI-Ly1, DB, and FARAGE in Figures 4D and 4E), were subjected to densitometric analysis.
Arbitrary units for protein lysates were normalized to actin levels. EC50 of ABT-737 of DLBCL cells were calculated from dose-re-
sponse curve experiments shown in Figures 3 and 4A. t(14:18) translocation status determined by standard cytogenetic analysis.levels by themselves offered no ability to predict response
to ABT-737 (Figures 5F and 5G). While using a nonpara-
metric comparison, it is notable that the presence of the
t(14;18) was also strongly correlated to sensitivity to
ABT-737 (p < 0.0001, Mann-Whitney rank sum test, see
Table 1), supporting its mechanism of killing via interaction
with BCL-2. All of these findings support our model that
BIM only predisposes to BCL-2 dependence and
response to ABT-737 when it is sequestered by BCL-2,
priming the cell for a death that is prevented by BCL-2.
BCL-2 Overexpression Does Not Cause Sensitivity,
but BIM Knockdown Reduces Sensitivity to ABT-737
While BIM:BCL-2 levels correlate well with ABT-737 sen-
sitivity, so do BCL-2 levels. Our hypothesis was that the
level of the BIM:BCL-2 complex is mechanistically critical,
and the correlation of sensitivity to ABT-737 with BCL-2
simply reflects the requirement for sufficient BCL-2 to
sequester the amount of BIM generated by death signal-
ing. However, it remained a formal possibility that BCL-2
levels alone dictated sensitivity by an obscure mecha-
nism. To test this possibility, we expressed BCL-2 in
SU-DHL8 and HT cells that were relatively resistant to
ABT-737 and had expressed low levels of BCL-2
(Figure 6A). By transfection with a BCL-2 cDNA, we ob-
tained BCL-2 expression levels comparable to those
from the ABT-737-sensitive cell line SU-DHL6. Low BIMexpression levels remained unaltered. Congruent with
our model and with prior results (Certo et al., 2006; Olters-
dorf et al., 2005), overexpression of BCL-2 alone did not
confer sensitivity (Figure 6B).
If the presence of BIM sequestered by BCL-2 dictates
sensitivity, then we would predict a knockdown of BIM
to reduce sensitivity. We used shRNA against BIM to
reduce BIM levels in the cell line most sensitive to ABT-
737, OCI-Ly1 (EC50 = 21 nM; Figure 6C). Reduction of
BIM levels caused a reduced sensitivity to ABT-737 (Fig-
ure 6D). Furthermore, we examined the effect of BIM
reduction on BCL-2 dependence at the mitochondrial
level using BH3 profiling. Parental OCI-Ly1 mitochondria
revealed a BCL-2-dependent pattern upon BH3 profile,
and a mitochondrial sensitivity to the compound, consis-
tent with the cell line’s sensitivity to ABT-737 (Figure 6E).
Key to this analysis is the response to the sensitizer BAD
BH3 peptide, which maps tightly with ABT-737 sensitivity
(Certo et al., 2006). In an abbreviated BH3 profile, we
confirmed that reduction in BIM levels had no effect on
sensitivity to the activator BH3 peptide BIM BH3
(Figure 6F). However, decrease in BIM levels caused re-
duction in mitochondrial response to both BAD BH3 and
ABT-737. Note that mitochondrial response to ABT-737
correlated with cellular response in other cell lines as
well, supporting mitochondrial BCL-2 as the target for
ABT-737 action (Figure S3). This finding implicatesCancer Cell 12, 171–185, August 2007 ª2007 Elsevier Inc. 177
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event in the mitochondrial and cellular toxicity resulting
from antagonism of BCL-2 by ABT-737 in lymphoma.
Figure 7A shows a summary of our classification of cells
into three classes based on type of apoptotic block. It
occurred to us that many types of conventional chemo-
therapy also kill via the mitochondrial apoptotic pathway.
If our classification is accurate, we would predict that
agents that rely on the mitochondrial pathway for killing
would be more active against the ‘‘primed’’ subset of class
C compared to the ‘‘unprimed’’ subset of class A and B.
To test this hypothesis, we treated seven cell lines that
had been already classified by BH3 profiling (summarized
in Figure 7B) with agents that have been characterized as
Figure 5. Levels of BCL-2 and BCL-2:BIM Complex Are Best
Predictors of ABT-737 Sensitivity in DLBCL Cells
(A–G) BCL-2 family proteins analyzed by immunoblotting in DLBCL cells
and EC50 of ABT-737 of those cells (both listed in Table 1) were subjected
to statistical analysis via a linear regression model. y axis is log EC 50 of
ABT-737 (nM); x axis represents the arbitrary units of different BCL-2
family proteins or immunoprecipitates as indicated, obtained by densito-
metric scanning of immunoblots. Colors of filled squares corresponds to
the color code used in Figure 4A: most sensitive to ABT-737 in red, inter-
mediate sensitivity in yellow, and low sensitivity in blue.178 Cancer Cell 12, 171–185, August 2007 ª2007 Elsevier Inc.inducing apoptosis through the mitochondrial pathway
(Decaudin et al., 1997; Kojima et al., 1998; Wei et al.,
2001; Zong et al., 2004). Strikingly, in each case we found
that the primed subset was more sensitive than the
unprimed subset (Figures 7C–7E). The case of the puta-
tively BFL-1-dependent PFEIFFER cell line is particularly
instructive, as it shows that it is the state of being ‘‘primed’’
rather than specifically being sensitive to ABT-737 that
dictates sensitivity to the chemotherapy drugs. It has
been shown previously that alkylating agents like N-
methyl-N0-nitro-N-nitrosoguanidine (MNNG) can use the
intrinsic apoptotic pathway but can also induce death
via an alternative PARP-dependent necrotic pathway
independent of BCL-2 family proteins (Zong et al., 2004).
Specifically, MEFs from mice lacking BAX and BAK were
highly resistant to etoposide, but not to MNNG. Therefore,
we would predict that lymphoma lines would respond to
MNNG independent of their classification by BH3 profil-
ing. That is precisely what we found (Figure 7F), providing
confirmation in a human cancer setting of what was previ-
ously proposed in genetically modified murine cells.
Therefore, just as BH3 profiling can identify cancer cells
(class C) that are likely to respond to agents using the
intrinsic apoptotic pathway like vincristine, etoposide,
and adriamycin, it may also be able to identify those cells
(class A or B) that will selectively respond to alkylating
agents. BH3 profiling therefore can provide fundamental
parameters of a cell’s phenotype.
DISCUSSION
Many, perhaps even all, cancer cells require blocks in
death signaling for oncogenesis and maintenance of the
malignant phenotype (Green and Evan, 2002; Hahn and
Weinberg, 2002). Since the most common abnormalities
of cancer behavior, like genomic instability and oncogene
activation, signal death via the mitochondrial apoptotic
pathway, it seems necessary that cancer cells select
means for blocking apoptosis at the mitochondrion. Using
diffuse large B cell lymphoma as a model, we show that
blocks in the intrinsic pathway of apoptosis may be bro-
ken into three main classes, and that BH3 profiling can
assign a cancer cell to one of these three classes (Fig-
ure 7). Due to the prior lack of availability of a technology
to make such distinctions, such a classification has previ-
ously been lacking. We hope its introduction will facilitate
systematic study of cancer cells and how to kill them.
A class A block occurs when normal generation of
proapoptotic activators by aberrant behavior is inhibited.
Mitochondrial outer membrane permeabilization requires
activation and oligomerization of BAX and BAK. Activation
of BAX and BAK requires the action of activator BH3-only
proteins. These proteins include BID and BIM, but other
proteins may possibly operate as activators, including
PUMA and p53 (Chipuk et al., 2004; Kim et al., 2006; Letai
et al., 2002). Given the difficulty in identifying BH3 do-
mains from primary sequence, there may well be several
undiscovered important activator proteins, and even mol-
ecules that activate BAX and BAK without a discernable
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BH3 Profiling Sorts Apoptotic Blocks in CancerBH3 domain. The mechanisms by which aberrant behav-
ior such as genomic instability and oncogene activation
generate death signals via BH3-only proteins is as yet
poorly understood, and therefore how this upstream
‘‘pre-BH3-only’’ signaling is attenuated is also poorly
understood. Since transcriptional activation certainly can
induce upregulation of activators, loss of transcriptional
proteins like p53 may certainly play a role. Posttransla-
tional modifications, including phosphorylation, also are
important in regulating function of BH3-only proteins, so
we can speculate that the modification of phosphorylation
cascades that occurs in cancer may play a role in estab-
lishing a class A block. This is an area of ongoing study.
A class B block occurs when there is a significant loss of
BAX and BAK. It has been shown that the presence of
either BAX or BAK is necessary for apoptotic signaling
through the mitochondrial pathway (Wei et al., 2001;
Zong et al., 2001). Again, it is not clear how this might
occur, whether by genetic or epigenetic means, but we
observed its spontaneous occurrence in the case of SU-
DHL10. Given how profound the block in apoptosis is
that results from loss of BAX and BAK, it is reasonable
to ask why such a loss does not occur more often in can-
cer. The answer well may lie in other nonapoptotic roles
played by BAX and BAK, including control of mitochon-
drial fusion and calcium homeostasis (Karbowski et al.,
2006; Scorrano et al., 2003). Loss of these roles may be
too costly to allow for frequent selection in natural
oncogenesis.
One can readily identify examples of the genetic basis of
the class C block in certain human cancers. The t(14;18)
found in follicular lymphoma and some DLBCL drives
overexpression of the antiapoptotic BCL-2 protein (Bakh-
shi et al., 1985; Cleary and Sklar, 1985; Tsujimoto et al.,
1985). In CLL, there is evidence that chromosomal dele-
tions causing loss of micro-RNAs that downregulate
BCL-2 expression are responsible for BCL-2 expression
in a large proportion of cases of CLL (Cimmino et al.,
2005). It is notable that, in this study, nine of the ten cell
lines that bear the t(14;18) are dependent on BCL-2 as
shown by sensitivity to ABT-737 and BH3 profiling (Table
1). This supports the model that high levels of expression
of antiapoptotic proteins in cancer cells license oncogenic
phenotypes, which generate death signals carried by
BH3-only proteins. These phenotypes, which would be
intolerable without antiapoptotic protection, include geno-
mic instability, hyperproliferation, and oncogene activa-
tion. Thus, when selected for during oncogenesis, the
BCL-2 resulting from the t(14;18) may not provide any
additional resistance to cytotoxic agents, as it is already
occupied by BH3-only death signals generated by cancer
phenotypes.
Superficially, this model might seem to contradict the
traditional view of BCL-2 expression as uniformly provid-
ing protection from cytotoxic insults like chemotherapy.
Yet it is important to understand the context under which
this view arose. BCL-2 was initially studied via overex-
pression in stable cell lines that had already reached an
equilibrium with their in vitro environment. In these circum-stances, additional BCL-2 provided extra antiapoptotic
reserve which produced resistance to a variety of insults,
including genotoxic agents, growth factor withdrawal, and
broad spectrum kinase inhibition. However, cancers
cannot select for antiapoptotic protein expression in the
expectation that they will some day be subject to apopto-
tic signaling from chemotherapy. Rather, the only
selection pressure available during oncogenesis is that
generated by the cancer’s own aberrant behavior. While
the magnitude of death signaling may vary with an individ-
ual cancer cell’s local environment or position in cell cycle,
it seems likely that much of the antiapoptotic reserve that
might otherwise be provided by the selected BCL-2
expression will be eliminated by ongoing prodeath signal-
ing. To put it simply, in cell culture overexpression models,
BCL-2 is largely ‘‘empty,’’ whereas BCL-2 is largely
already ‘‘full’’ when it is selected for in cancer. This may
offer an explanation of the high sensitivity of certain can-
cer cells to chemotherapy and radiation, a sensitivity
that often lacks adequate molecular explanation. Strong
support for this view can be found in the clinically obvious,
but perhaps scientifically underappreciated, observation
that BCL-2-expressing follicular lymphoma and CLL are
among the most chemosensitive cancers known. An ex-
planation for this seeming paradox may be found in the
observation that, in CLL cells, the BCL-2 is primed with
abundant amounts of BIM, rendering CLL ‘‘primed for
death’’ (Del Gaizo Moore et al., 2007).
A particularly significant finding here is that BH3 profil-
ing can be used to predict sensitivity to conventional che-
motherapy agents. As predicted, cells that are ‘‘primed’’
with prodeath signaling proteins, class C cells, respond
better to chemotherapy agents using the intrinsic apopto-
tic pathways like vincristine, etoposide, or adriamycin.
Perhaps just as important, we can identify cells, class A
or B, that may be unlikely to respond to those agents,
but rather more likely to benefit from alkylating agents.
This paradigm certainly suggests itself to clinical applica-
tion, but clearly more work on a wider range of cell types
and wider range of agents is necessary before clinical
use. This approach is especially attractive as BH3 profiling
can be performed on tumor mitochondria without the need
for ex vivo cell culture (Del Gaizo Moore et al., 2007; Letai
et al., 2004), thus overcoming one of the major hurdles that
has plagued determination of chemosensitivity in vitro.
While needing confirmation, this model is thus far sup-
ported by the observation that previously untreated CLL,
which we found to be uniformly a class C disease (Del
Gaizo Moore et al., 2007), is also quite uniformly sensitive
to a wide range of chemotherapeutic agents.
BH3 profiling proves to be a very useful tool in detect-
ing each of the three classes of block, and furthermore,
detecting which antiapoptotic protein is most critical for
survival in the case of a class C block. Consequently,
BH3 profiling proves to be an excellent predictor of
cellular response to ABT-737. Cells that show a class
C block and BCL-2 dependence on BH3 profiling
are predicted to be sensitive to ABT-737, and those
with other profiles as relatively resistant. On this basis,Cancer Cell 12, 171–185, August 2007 ª2007 Elsevier Inc. 179
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BH3 Profiling Sorts Apoptotic Blocks in CancerFigure 6. Overexpression of BCL-2 Alone Does Not Confer Cell Sensitivity to ABT-737-Resistant Cells, but BIM Loss Confers
Resistance to Sensitive Cells
(A) Immunoblot of BCL-2 and BIM levels in whole cell lysates (left) and anti-BCL-2 immunoprecipitates (right) in HT and SU-DHL8 stable clones. The
endogenous BCL-2 in SU-DHL6 cells is shown for comparison. P, parental cells; vec, vector-transfected cells; bcl-2, FlagBCL-2-transfected cells.
(B) Dose-response curve experiments were carried out in parental and vector- and Flag-BCL-2-transfected HT and SU-DHL8 cells as in Figure 4.
Shown is the mean of three experiments; error bars show standard deviation.
(C) Immunoblots of OCI-Ly1 parental (p), Luc ShRNA, and BIM ShRNA knockdown stable cells. c1, c3 and c15, c22 are two representative clones for
OCI-Ly1 Luc ShRNA and BIM ShRNA cells, respectively. Various antibodies against BIM, BCL-2, MCL-1, BAX, BAK, and loading control ACTIN were
used for immunoblot analysis.
(D) Dose response to ABT-737 experiments in OCI-Ly1 Luc ShRNA and BIM ShRNA clones. Luc (c1, c3) and BIM (c15, c22) cells were treated with
increased doses of ABT-737 for 4 hr and stained with Annexin-V-FITC for flow cytometry analysis as in Figure 4.
(E) BH3 profiling for OCI-Ly1 parental cells. Mitochondria were isolated from OCI-Ly1 parental cells and incubated with a panel of BH3-only peptides
(100 mM), ABT-737, and enantiomer (both were 1 mM). Results were shown as percentage minus DMSO values and normalized to BIM-treated sample.180 Cancer Cell 12, 171–185, August 2007 ª2007 Elsevier Inc.
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BH3 Profiling Sorts Apoptotic Blocks in CancerSU-DHL4, SU-DHL6, TOLEDO, and OCI-Ly1 were all
correctly predicted to be sensitive to ABT-737, while
SU-DHL8, SU-DHL10, and PFEIFFER were all correctly
predicted to be resistant. While we had previously shown
in CLL that a BCL-2 BH3 profile corresponded to sensi-
tivity to ABT-737, the surprising homogeneity of the
leukemia samples studied (all were exquisitely sensitive
to ABT-737) did not allow for the testing of the ability
of ABT-737 to discriminate between sensitive and resis-
tant cell lines in a heterogeneous group of samples (Del
Gaizo Moore et al., 2007).
This same heterogeneity allowed for the testing of
protein correlates to ABT-737 sensitivity. We found that
sensitivity to ABT-737 correlated most tightly with abun-
dance of BCL-2 and BCL-2:BIM complex (Figures 5A
and 5B). This finding is consistent with our model in which
priming of BCL-2 with activators is the primary determi-
nant of BCL-2 dependence (Figure 7). To demonstrate
that BCL-2 expression in the absence of priming was
insufficient to cause ABT-737 sensitivity, we showed
that overexpression of BCL-2 failed to convert a resistant
cell line to a sensitive cell line (Figures 6A and 6B). These
results were congruent with results we obtained in model
systems, which showed that BCL-2 expression in the
absence of priming was insufficient to cause sensitivity
to ABT-737 (Certo et al., 2006). To demonstrate that
BIM’s priming of BCL-2 was critical for the dependence
on BCL-2, we showed that knockdown of BIM expression
decreased sensitivity of both cells and mitochondria to
BCL-2 antagonism (Figures 6C–6F). A weaker correlation
was found linking sensitivity to BAX and BCL-2:BAX levels
(Figure 5D). This may suggest that BCL-2 can be primed
with BAX in certain lymphoma cells. If so, this is likely to
reflect sequestration of BAX that has already been
activated, as BCL-2 binds poorly to BAX before it
undergoes the allosteric changes that accompany
activation.
Recent work in model systems and acute myelogenous
leukemia has suggested that expression of MCL-1 is a key
determinant of resistance to ABT-737 (Konopleva et al.,
2006; Lin et al., 2006; van Delft et al., 2006). It is indeed
very plausible that high levels of MCL-1 expression are
likely to render a cell resistant to ABT-737 treatment.
Our results indicate, however, that while MCL-1 levels
may well influence resistance, lack of MCL-1 is not the
sole determinant of sensitivity, nor likely the most critical,
at least in lymphoma. For instance, a simple inspection of
Table 1 shows that OCI-Ly1 and OCI-Ly4 have nearly
identical levels of MCL-1, but EC50 values that differ by
more than 100-fold. Other similar examples are seen in
Table 1. A more comprehensive assessment is found in
the linear regression modeling, which reveals a suggestive,
but fairly weak correlation between MCL-1 and log EC50
(Figure 5E). It remains to be seen whether other cell types
show a stronger correlation between MCL-1 and EC50 ofCABT-737. Mechanistically, we believe it is likely that
MCL-1 overexpression would protect cells from ABT-
737, as the drug cannot target MCL-1. However, while
high levels of expression of MCL-1 may be expected to
induce resistance, results here and elsewhere (Certo
et al., 2006; Oltersdorf et al., 2005) confirm that even total
absence of MCL-1 is unlikely to cause sensitivity to BCL-2
antagonism unless BCL-2 is present and primed with
prodeath activator BH3-only proteins.
Recently, a report suggested that there are circum-
stances in which activation of BAX or BAK by BID or
BIM is dispensable to the MOMP required for apoptosis
in the intrinsic pathway (Willis et al., 2007). However, our
results here further support the important role of BIM in ac-
tivating BAX and BAK. Using a combination of BH3 profil-
ing and ABT-737 treatment, we are able to determine
which lymphoma lines are most dependent on BCL-2
function for ongoing survival. Remarkably, dependence
on BCL-2 correlates very tightly, even quantitatively,
with amount of BIM:BCL-2 complex (Figure 5B). Reduc-
tion of BIM reduces this dependence (Figures 6C, 6D,
and 6F). Furthermore, overexpression of BCL-2 in the
absence of BIM alone does not induce BCL-2 depen-
dence (Figures 6A and 6B). BCL-2 dependence instead
requires significant amounts of BIM to be sequestered
by BCL-2. It is difficult to understand how BIM:BCL-2
complex levels would so quantitatively confer depen-
dence on BCL-2 in a model in which BIM plays no role in
activating BAX or BAK. These results are therefore less
consistent with the ‘‘indirect activation’’ model in which
the exclusive antiapoptotic function of BCL-2 is to bind
unspecified subsets of BAX or BAX (Willis et al., 2007).
They are instead more consistent with a model in which
BCL-2 sequesters activators like BIM from activating
BAX or BAK, resulting in a ‘‘primed’’ cell that is dependent
upon BCL-2 function. It is worth noting that we cannot,
and do not, claim that BIM or BID are the only activators.
Indeed, evidence already exists that activation of BAX and
BAK can occur via PUMA or p53, and there is no reason to
believe that all activators have been discovered (Chipuk
et al., 2004; Kim et al., 2006).
In this study, we focused on a single disease, diffuse
large B cell lymphoma. We found that, in a group of
cells that were superficially quite similar, vital molecular
details could be revealed by BH3 profiling and by
protein analysis driven by BH3 profiling results. These
details explained an important therapeutic phenomenon,
sensitivity to BCL-2 antagonism by ABT-737. BH3 profil-
ing of lymphoma cells provides a valuable and unique
insight into the diverse mechanisms maintaining their
survival, immediately suggesting targets for therapeutic
intervention. We suggest that, by identifying the class
of apoptotic block, BH3 profiling can provide valuable
information about a fundamental biological parameter
of any cell.(F) BH3 profiling for OCI-Ly1 Luc shRNA c1 and BIM shRNA c15 stable clones. Mitochondria were isolated from the respective clones and subjected to
incubation with peptides BIM BH3 (10 mM), BAD BH3 (3 mM), or ABT-737 (30 nM).
(D)–(F) show the mean of three experiments; error bars show standard deviation.ancer Cell 12, 171–185, August 2007 ª2007 Elsevier Inc. 181
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BH3 Profiling Sorts Apoptotic Blocks in CancerFigure 7. Three Classes of Apoptotic Escape for Cancer Cells Predict Sensitivity to Conventional Chemotherapy Agents
(A) Class A cells survive due to suppression of activator upregulation. Class B cells survive due to loss of BAX and BAK, the effector BCL-2 family
proteins. Class C cells survive due to high expression of antiapoptotic proteins like BCL-2. In the middle are shown representative actual BH3 profiles,
and at right are expected responses to antagonists of antiapoptotic proteins like ABT-737.182 Cancer Cell 12, 171–185, August 2007 ª2007 Elsevier Inc.
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Cell Lines
DLBCL cells were cultured in suspension with RPMI 1640 medium or
Iscove’s modified Dulbecco’s medium (Invitrogen) supplemented
with 10% heat-inactivated fetal bovine serum (Sigma, F-6178), L-
glutamine, and penicillin/streptomycin (Invitrogen).
Stable HT and SU-DHL8 cell lines carrying pCI-Neo.FlagBcl2 or
control vector pCI-Neo.Flag were obtained by electroporation of plas-
mids into lymphoma cells (Gene Pulser II, Bio-Rad) followed by selec-
tion with G418 (Sigma, 1 mg/ml).
BIM ShRNA (pLKO.1puro-Bim) or Luc ShRNA (pLKO.1puro-lucifer-
ase) was obtained from the RNAi Consortium (Cambridge, MA).
Knockdown cells were prepared by infecting lymphoma cells with ret-
roviral supernatants produced by cotransfection of 293T cells with
pCMVDR8.91, pMD.G, and either pLKO.1puro-Bim or pLKO.1puro-
luciferase (Del Gaizo Moore et al., 2007; Ernst et al., 2004). Stable
clones were selected with puromycin (Sigma, 250 ng/ml) and main-
tained by changing cell culture media daily with fresh L-glutamine
(2 mM).
BH3 Profiling
Mitochondria were purified from DLBCL cells by mechanical disruption
followed by differential centrifugation, as previously described (Letai
et al., 2002). Mitochondrial suspensions were made at 0.1 mg
protein/ml in experimental buffer and exposed to BH3 domain pep-
tides at 100 mM for 40 min at room temperature. Peptides used in
this assay were synthesized by Tufts University Core Facility and
purified by HPLC. Identity was confirmed by mass spectrometry.
Stock solutions were made in dimethyl sulfoxide (DMSO). Peptide
sequences are as previously reported (Certo et al., 2006). ABT-737
and its negative control enantiomer (Enant) were kindly provided by
Abbott Laboratories (Abbott Park, IL). Release of cytochrome c was
determined by a comparison of cytochrome c in the pellet and super-
natant quantitated by ELISA (R&D Systems).
Cell Viability Assay
DLBCL cells were treated with ABT-737 or enantiomer as described in
the figure legends. DMSO was used as a solvent-only negative control.
After treatments, cells were stained with fluorescent conjugates of
Annexin-V (BioVision) and analyzed on a FACSCalibur machine
(Becton Dickinson). Viable cells are Annexin V-FITC negative. Vincris-
tine, etoposide, and adriamycin were obtained from Sigma. MNNG
was obtained from Fisher.
Immunoprecipitation and Immunoblotting
Protein lysates were obtained by cell lysis in Triton X-100 buffer (50 mM
Tris-HCL [pH 7.4], 150 mM NaCl, 5 mM MgCl2, 1 mM EGTA, 10% Glyc-
erol, 1% Triton X-100 [Sigma]). Immunoprecipitation was performed in
600 ml lysates containing 400 mg proteins, which was precleared by
centrifugation followed by exposure to 12 ml (50% slurry) protein A
beads (Santa Cruz) at 4C for 1 hr. Cleared extracts were incubated
overnight with protein A beads pre-exposed for 1 hr to anti-BCL-2
antibody (6C8, PharMingen). Immunoprecipitates were then washed
three times with Triton X-100 buffer and boiled in loading buffer
(Invitrogen). Protein samples were electrophoretically separated on
NuPAGE 10% Bis-Tris polyacrylamide gels (Invitrogen). Antibodies
were used to detect the following proteins on membrane: BCL-2
(Epitomics, 1017-1); BCL-xL (kind gift from Larry Boise); BCL-w (Onco-
gene, 75-1); MCL-1 (Santa Cruz, S-19); BIM (Calbiochem, 22-40); BID
(Santa Cruz, FL-195); BAX (Santa Cruz, N20); BAK (Upstate, NT), Actin
(Chemicon, MAB1501).Western Blot Protein Quantification
Densitometry of protein bands were acquired using an AlphaImager
EC gel documentation system (Alpha Innotec Germany), and bands
were analyzed with the spot densitometry analysis tool (Alpha Ease
FC software, version, 4.1.0).
mRNA Comparison
Quantities of BFL-1 mRNA were measured according to the manufac-
turer’s specification on an Affymetrix chip using the 205681_at probe.
Statistical Analysis
GraphPad Prism 4 software was used to determine EC50 values by
nonlinear dose-response curve fitting. Correlation of EC50 with BCL-
2 family proteins was obtained by a linear regression model.
Supplemental Data
The Supplemental Data include three supplemental figures and can be
found with this article online at http://www.cancercell.org/cgi/content/
full/12/2/171/DC1/.
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